UBS AM Portfolio holdings
UBS Asset Management (UBS AM), a division of UBS Group AG with origins tied to the bank’s founding in 1862, is headquartered in Zurich, Switzerland, and manages hundreds of billions in assets for institutional, intermediary, and wealth management clients globally. Specializing in a broad range of investment strategies—including equities, fixed income, multi-asset, alternatives, and sustainable investing—UBS AM leverages the firm’s extensive research capabilities and global network to deliver tailored solutions. Known for its focus on risk management and innovation, it offers products like ETFs, index funds, and private market investments, catering to diverse needs from pension funds to high-net-worth individuals. As part of UBS’s broader ecosystem, UBS AM combines Swiss precision with a commitment to ESG principles, solidifying its position as a leader in the asset management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abbott
ABT
|
+$950M |
| 2 |
Linde
LIN
|
+$886M |
| 3 |
Amgen
AMGN
|
+$812M |
| 4 |
Pinduoduo
PDD
|
+$400M |
| 5 |
Advanced Micro Devices
AMD
|
+$240M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ametek
AME
|
+$475M |
| 2 |
Microsoft
MSFT
|
+$266M |
| 3 |
Amazon
AMZN
|
+$221M |
| 4 |
VMW
VMware, Inc
VMW
|
+$197M |
| 5 |
Canadian Pacific Kansas City
CP
|
+$140M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 28.09% |
| 2 | Healthcare | 14.47% |
| 3 | Financials | 11.11% |
| 4 | Consumer Discretionary | 10.49% |
| 5 | Industrials | 7.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2551
Clarus
CLAR
$126M
| $130K | ﹤0.01% |
13,754
-18,108
| -57% | -$170K |
|
|
NGM
2552
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $128K | ﹤0.01% |
31,431
| – | – |
|
2553
Evolv Technologies
EVLV
$996M
| $128K | ﹤0.01% |
40,900
| – | – |
|
2554
SES AI
SES
$188M
| $128K | ﹤0.01% |
43,234
| – | – |
|
2555
Codexis
CDXS
$159M
| $126K | ﹤0.01% |
30,386
-56,698
| -65% | -$297K |
|
2556
Inovio Pharmaceuticals
INO
$83.9M
| $124K | ﹤0.01% |
12,610
| – | – |
|
2557
Sana Biotechnology
SANA
$860M
| $124K | ﹤0.01% |
37,818
-14,800
| -28% | -$59.1K |
|
2558
C4 Therapeutics
CCCC
$389M
| $123K | ﹤0.01% |
39,287
+9,994
| +34% | +$58.8K |
|
2559
Cosan
CSAN
$3.02B
| $123K | ﹤0.01% |
+10,408
| New | +$125K |
|
2560
Invesco Mortgage Capital
IVR
$763M
| $122K | ﹤0.01% |
+11,029
| New | +$142K |
|
|
RAD
2561
DELISTED
Rite Aid Corporation
RAD
| $121K | ﹤0.01% |
54,060
-25,635
| -32% | -$85K |
|
|
PSTX
2562
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
| $120K | ﹤0.01% |
+39,000
| New | +$234K |
|
2563
Clover Health Investments
CLOV
$2.24B
| $120K | ﹤0.01% |
141,869
-203,084
| -59% | -$222K |
|
|
TSP
2564
DELISTED
TuSimple Holdings Inc. Class A Common Stock
TSP
| $118K | ﹤0.01% |
80,385
+50,565
| +170% | +$95.6K |
|
2565
Amneal Pharmaceuticals
AMRX
$6.02B
| $118K | ﹤0.01% |
84,912
| – | – |
|
2566
FuboTV Inc
FUBO
$259M
| $117K | ﹤0.01% |
8,073
| – | – |
|
2567
AtaiBeckley Inc
ATAI
$2.65B
| $114K | ﹤0.01% |
63,211
| – | – |
|
2568
Kiniksa Pharmaceuticals
KNSA
$6.12B
| $114K | ﹤0.01% |
10,608
-19,400
| -65% | -$256K |
|
2569
Precigen
PGEN
$1.98B
| $113K | ﹤0.01% |
107,073
-25,810
| -19% | -$37.2K |
|
|
LOGC
2570
DELISTED
ContextLogic
LOGC
| $113K | ﹤0.01% |
8,415
+947
| +13% | +$16.1K |
|
|
ONTF
2571
DELISTED
ON24
ONTF
| $112K | ﹤0.01% |
12,777
| – | – |
|
2572
Telos
TLS
$333M
| $112K | ﹤0.01% |
44,084
| – | – |
|
|
SI
2573
DELISTED
Silvergate Capital Corporation
SI
| $110K | ﹤0.01% |
67,732
+33,175
| +96% | +$360K |
|
2574
Smartbird Inc
BIRD
$19.6M
| $107K | ﹤0.01% |
4,462
| – | – |
|
|
GTHX
2575
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $106K | ﹤0.01% |
39,600
+27,300
| +222% | +$131K |
|
Similar funds
UBS AM's Q1 2023 Portfolio in Review
As of Q1 2023, UBS AM held 2,762 positions worth $206B, up 8.3% from $191B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
UBS AM's Q1 2023 filing shows 231 new, 1,328 increased, 856 reduced and 85 closed positions. Its largest new stake was Amgen: 3,308,425 shares worth $800M. The largest sale was Ametek, an estimated $475M.
By sector, the portfolio is most concentrated in Technology at 28% of assets, up from 25% a quarter earlier, followed by Healthcare and Financials.
- UBS AM's largest Q1 2023 buy was Amgen: 3,308,425 shares worth $800M.
- UBS AM added most to Abbott in Q1 2023, an estimated $950M increase.
- UBS AM's biggest Q1 2023 reduction was Ametek, cutting an estimated $475M.
- UBS AM fully exited SVB Financial Group in Q1 2023, selling an estimated $77.3M.
- UBS AM's ten largest holdings make up 22% of its $206B portfolio in Q1 2023.
- UBS AM opened 231 new positions and closed 85 in Q1 2023.
- UBS AM's portfolio value rose 8.3% quarter-over-quarter to $206B.
Based on UBS AM's 13F filing for Q1 2023, filed 15 May 2023.